Undisclosed CD137xCD122 multi-agonist
/ Ankyra Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Anchored immunotherapy with CD137 (4-1BB) and CD122 (IL-2/15Rβ) multi-agonists induce monotherapy anti-tumor immunity and abscopal responses without systemic toxicity
(SITC 2026)
- No abstract available
Monotherapy • Oncology • IL2 • TNFRSF9
1 to 1
Of
1
Go to page
1